response of debtors to the reports of eric m....

1

IN THE UNITED STATES BANKRUPTCY COURTFOR THE EASTERN DISRICT OF PENNSYLVANIA

In Re:

KidsPeace Corporation, et. al.1

Debtors.

Chapter 11

Jointly Administered

Case No. 13-14508 (REF)

RESPONSE OF DEBTORS TO THE REPORTS OF ERIC M. HUEBSCHER ANDHUEBSCHER & CO. AS PATIENT CARE OMBUDSMAN OF THE DEBTORS

In the PCO’s Supplemental Report, the PCO reported about a Letter2 that the PCO

became aware of that was authored by a Mental Health Technician and signed by other

employees of the Debtors. It is the Debtors’ understanding that PCO reported the Letter to the

Department of Public Welfare on or about November 7, 2013 as a complaint. As a result, on

November 20, 2013, the Department of Public Welfare Office of Mental Health and Substance

Abuse Services (“OMHSAS”) conducted a survey of the Hospital to examine the following areas

of concern:

1. Increased Client Acuity Levels;

2. Food Shortages;

3. Excessive Use of Restraints and Isolation;

4. High Staff Turnover and Staff Vacancies;

5. Consumers Sleeping on the Floor;

6. Inappropriate Staffing Ratios; and

1 The Debtors and the last four digits of their respective taxpayer identification numbers are as follows:KidsPeace Corporation (3394); KidsPeace Children’s Hospital, Inc. (4910); KidsPeace Mesabi Academy, Inc. (4179); KidsPeace NationalCenters, Inc. (4908); KidsPeace National Centers of Georgia, Inc. (7440); KidsPeace National Centers of New England, Inc. (1326); KidsPeaceNational Centers of North America, Inc. (4765); Iron Range School, Inc. (0561); and KidsPeace National Centers of New York, Inc. (1888). TheDebtors’ address is 5300 KidsPeace Drive, Orefield, Pennsylvania 18069. References in this report to the Debtors refer to at least one of theDebtor entities.

2Defined on page 3 of 8 in the PCO’s Supplemental and Special Report

Case 13-14508-ref Doc 722 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Main Document of 2

2

7. Inadequate Staff Orientation.

In a letter dated December 18, 2013 (attached hereto as Exhibit A), OMHSAS informed

the Debtors of their findings and indicated that there were “No deficiencies…identified at the

time of the visit.”

Upon review of the PCO’s Reports and Responses by the Debtor, the Board of Directors

of the Debtors directed management to engage an independent reviewer to conduct an

assessment of its health care operations in Pennsylvania. The PCO made a similar

recommendation to the Debtors. The Debtors engaged such an individual, Dr. Oscar Bukstein.

Dr. Bukstein’s completed an Independent Review and submitted the review to Debtors on

December 17, 2013 (attached hereto as Exhibit B).

Respectfully submitted,

KIDSPEACE CORPORATION

By: /s/ William IsemannDate: January 9, 2013 WILLIAM ISEMANN

Case 13-14508-ref Doc 722 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Main Document of 2

Case 13-14508-ref Doc 722-1 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit A Page 1 of 2

Case 13-14508-ref Doc 722-1 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit A Page 2 of 2

Case 13-14508-ref Doc 722-2 Filed 01/09/14 Entered 01/09/14 17:13:14 Desc Exhibit B Page 1 of 32

Revised November 16, 2013

1

CURRICULUM VITAE

I. General Biographical Information

A. Personal

1. Name: Oscar Gary Bukstein, M.D.

2. Citizenship: United States of America

3. Education:

a. UNDERGRADUATE:

Washington University 9/1972-5/1974

St. Louis, Missouri

University of Missouri 6/1974-5/1976

Bachelor of Arts, Philosophy, 1976

Columbia, Missouri

b. GRADUATE:

University of Texas 8/1978-6/1980

School of Public Health Masters in Public Health (MPH) 1980

Houston, Texas

University of Texas 8/1979-5/1983

Medical Branch Doctor of Medicine (MD), 1983

Galveston, Texas

c. POST GRADUATE:

Psychiatry Internship 6/1983-6/1984

Western Psychiatric Institute and Clinic

University of Pittsburgh

Pittsburgh, Pennsylvania

Combined Residency 7/1984-6/ 1988

and Fellowship in General and Western Psychiatric Institute and Clinic

Child/Adolescent Psychiatry University of Pittsburgh,


B. Academic Appointments:

1. Current Visiting Professor of Psychiatry 10/2010- present

Director, Division of Child and Adolescent Psychiatry

Department of Psychiatry and Behavioral Sciences

The University of Texas Medical School at Houston



2

2. Previous ACADEMIC APPOINTMENTS

Assistant Professor 7/1988- 6/1997

Department of Psychiatry

Western Psychiatric Institute and Clinic/ University of Pittsburgh

Pittsburgh, PA

Associate Professor 6/1997- 4/2009



University of Pittsburgh School of Medicine

Professor of Psychiatry 4/2009-10/2010




Pittsburgh, PA

Adjunct Professor of Psychiatry 10/2010-present



Pittsburgh, PA

C. Other Advanced Training

NIMH Post-Doctoral Fellowship in Clinical. 7/1987-6/1988

Research Training in Psychiatry

Western Psychiatric Institute and Clinic/University of Pittsburgh


D. Other Information

1. HONORS & AWARDS

a. Hamilton F. Ford Award for Psychiatry in Medicine 1983

University of Texas Medical Branch

b. American Psychiatric Association/Mead Johnson Fellow 1985-1986

c. American Academy of Child and Adolescent Psychiatry

d. Outstanding Mentor Award - American Academy of Child and 2005, 2008

Adolescent Psychiatry

F, Dean’s Teaching Excellence Award

University of Texas Health Science Center 2011-2012

2. Board Certification

American Board of Psychiatry and Neurology (ABPN):

Board Certification - General Psychiatry, No. 33073 1990

Board Certification - Child and Adolescent Psychiatry, No 2725 1991

Board Certification - Addiction Psychiatry, No. 064 1993,

2003

3. Other Non-Academic positions

Medical Director, Adolescent Drug Abuse 8/1989-8/1992

& Psychiatric Treatment Program


Pittsburgh, PA



3

Medical Director, Pittsburgh Adolescent 9/1990-8/2000

Alcohol Research Center (PAARC)

Western Psychiatric Institute and Clinic/University of Pittsburgh

Pittsburgh, PA

Medical Director, Child and Parent Behavior Clinic: 9/1992-5/1997

Outpatient & Partial Hospitalization


Pittsburgh, PA

Medical Director, Attention Deficit Disorder Clinic 8/1993-9/2010

and Research Program



Pittsburgh, PA

Medical Director, Chronic Disorders 8/1995-6/2004

Treatment & Intervention Service (CACTIS)


Pittsburgh, PA

Director, Clinical Core, Pittsburgh Adolescent 9/1998 –8/2001

Alcohol Research Center (PAARC)



Pittsburgh, PA

Medical Director, Adolescent Substance Abuse 10/2003-10/2010

Treatment Program


Pittsburgh, PA

Medical Director, Appalachian Tri-State Node 9/2005-10/2010

NIDA Clinical Trials Network


Pittsburgh, PA

Staff Psychiatrist 2/2011-7/2013

Harris County Psychiatric Center

Houston, Texas

Director 6/2012-5/2013

UT Pediatric Bipolar Clinical Research Program

Houston, Texas

Changing Lives through Autism Spectrum Services 1/2011-7/2013

University of Texas Health Science Center

Houston, Texas

Medical Director 7/2013 – present

DePelchin Children’s Center



4

Houston, Texas

II Research Information

R01 MH Stimulant & Risperidone for Youth Co- Investigator 2008- NIMH

077676-01A2 with Severe Physical Aggression 10% effort 2012 $1,930,751

5R01HD Reading ICARD: Intervention Co-investigator 2010 $887,097

060617-02 for Children with Attention 10% effort 2014

and Reading Disorders

86-1063-86 Adolescent Suicide and Suicidal

Behavior

Interviewer

Training

1987-

88

WT Grant

Foundation

N/A Assessment of Personality in

Adolescents

Interviewer 1987-

88

MHCRC Pilot

Funding

N/A Affective Disorders and Substance

Abuse in Adolescents

Principal

Investigator

1989-

90

MHCRC Pilot

Funding

DA-05605-04 Drug Abuse Vulnerability:

Mechanisms and Manifestations –

Clinical Research Center

Training 1989-

94

NIDA

AA-08284-05 Alcohol Use Among Teenagers and

Infant Outcome

Co-Investigator 1989-

94

NIAAA

AA-05952-04 Adolescent Alcohol Abuse: Clinical

Research Center


95

NIAAA

MH 50467 Multi-Modal Treatment Study of

Attention-Deficit Hyperactivity

Disorder


98

NIMH

N/A Services needs and Concerns Co-Investigator 1994-

96

Mental Health

Research Center

AA-08746 Adolescent Alcohol Abuse:

Biobehavioral Manifestations- Clinical

Research Center


2000

NIAAA

N/A Double Blind, Fixed-Dose Study of

Transdermal Buspirone in ADHD

Principal

Investigator

1997-

98

Bristol-Myers

Squibb

N/A Screening, Initiation, Safety and

Efficacy of OROS (Methylphenidate)

Principal

Investigator

1998-

2000

ALZA Corp

MH57727 Effectiveness of Community Services

for Conduct Problems


2003

NIMH

N/A Treatment for Juvenile Sex Offenders Co-Investigator 1998-

2004

PA Commission

on Crime and

Delinquency

N/A Development and Outcomes of a Dual

Diagnosis Treatment Program for

Delinquent Youth

Principal

Investigator

2000-

04

PA Commission

on Crime and

Delinquency

K08 00280AA

Alcohol and Mental Disorders Among

ED-Treated Adolescents

Co-Investigator

2000-

05

NIAAA

N/A An Evaluation of the Safety and

Efficacy of CONCERTATM

(up to

72mg daily) in Adolescents with

ADHD

Principal

Investigator

2001-

02

McNeil

Pharmaceuticals



5

N/A

A Multicenter, Double-Blind Placebo-

Controlled, Safety and Efficacy Study

of Methylphenidate Transdermal

System in Pediatric Patients with

ADHD

Principal

Investigator

2001-

02

Noven

Pharmaceuticals

AA013370-01 Pharmacological Intervention for

Adolescents with Major Depressive

Disorder and Alcohol Use Disorders


05

NIAAA

AA000301 K-24: Psychopharmacology of

Adolescents with ADHD and Alcohol

use Disorders

Principal

Investigator

2001-

07

NIAAA

NS39087 Clonidine in ADHD Treatment &

Preschool Supplement


06

MH65420 In Vivo 31P Spectroscopy & MRI in

ADHD


06

NIMH

R21 DA

16631-03

Home-based Behavioral Therapy

(HBT): Psychosocial Intervention

Project for Early Adolescents with

Pre- or Early Substance Use Disorder

Principal

Investigator

2003-

08

NIDA

R01 MH

57727-09

Enhancing Long-Term Outcome in

Childhood Behavior Disorder


08

NIMH

N/A A Phase III Double-Blind, Multicenter,

Placebo-controlled Study to Evaluate

the Safety and Efficacy of

Methylphenidate Transdermal

System® (MTS) vs. CONCERTA

® in

Pediatric Patients aged 6-12 with

ADHD

Principal

Investigator

2004-

05

Shire

Pharmaceuticals

MH66775 Treatment of Adolescent Suicide

Attempters Study (TASA)

Principal

Investigator

2004-

07

NIMH

DA019142-01 Fluoxitine for MDD and Cannabis

Disorder in Young People

Co-Investigator

(10%)

2004-

08

NIDA

$340,859

N/A ADHD in a Detention Center

Population

Principal

Investigator

2005-

06

NIMH

DA020036-01

Clinical Trial Network: Appalachian

Tri-State Node

Co-Investigator

Medical

Director

(27.5%)

2005-

10

NIDA

$1,232,345

CTN 0028 Osmotic-Release Methylphenidate

(OROS MPH) for ADHD in

Adolescents with Substance Use

Disorder

Principal

Investigator

(site)

2006-

08

NIDA

AA016482 Northwestern Pennsylvania

Adolescent Alcohol Research

Cooperative

Co-Investigator

(10%)

2006-

09

NIAAA

$187,045

N/A A Double-Blind, Randomized,

Multicenter, Flexible-Dose Study

Evaluating the Efficacy and Safety of

SPD509 in Children Aged 6-12 with

Symptoms of Oppositionality and a

Principal

Investigator

2007-

08

Shire

Pharmaceuticals



6

Diagnosis of ADHD

N/A Family Focused Treatment for

Adolescents with Bipolar Disorder and

Substance Use Disorders

Co-Investigator

Mentor

(5%)

2007-

09

NARSAD

$60,000

N/A Association Between Substance Use

and Suicidality among Adolescents

with Bipolar

Co-Investigator

(5%)

2008-

09

American

Foundation for

Suicide

Prevention

N/A A Phase III, Double-Blind,

Randomized, Placebo-Controlled,

Multicenter, Dose Optimization Study

Evaluating the Efficacy and Safety of

SPD503 in Combination with

Psychostimulants in Children and

Adolescents aged 6-17 Years with a

Diagnosis of Attention

Deficit/Hyperactivity Disorder

(ADHD)

Principal

Investigator

2008-

10

Shire

Pharmaceuticals

R01MH

007676-01A2

Stimulant & Risperidone for Youth

with Severe Physical Aggression

Principal

Investigator

(30%)

2008-

12

NIMH

$1,930,751

R01 DA

012414-06

Development of Drug Abuse in ADHD

Adolescents

Co-Investigator

(5%)

2008-

13

NIDA

$218,419

N/A A Placebo-Controlled, Double-blind,

Parallel-group, Individualized Dosing

Study Optimizing Treatment of Adults

with ADHD to an Effective Response

with OROS® Methylphenidate

Principal

Investigator

2009-

10

McNeil

Pharmaceuticals

N/A A Phase III, Double-blind,

Randomized, Multicenter, Placebo-

controlled, Dose Optimization Study

Evaluating the Tolerability and

Efficacy of AM/PM Daily Dosing with

Extended-release Guanfacine

Hydrochloride in Children Aged 6-12

with a Diagnosis of ADHD

Principal

Investigator

2009-

10

Shire

Pharmaceuticals

B. National Scientific Participation:

1. Journal editorial boards

Journal of Child and Adolescent Substance Abuse 2000- Present

Journal of the American Academy of Child and Adolescent Psychiatry 2002-2007

Journal of ADHD and Related Disorders 2008- 2011

2. Review panels

a. NIAAA Special Emphasis Panel: Research In Medical Settings, 2002

b. National Institute on Drug Abuse (NIDA), Clin Trials Network, 2004-2005

c. NIDA Workgroup, Design Clinical Trials Network Study 2005

on Pharmacologic Treatment of Substance Use Disorder in ADHD

d. NIMH/NIH Loan Repayment Program, 2006-present

e. NIMH Mental Health Services IRG, ad hoc 2006-2007

f. Psychiatry Core Group, NICHD Workshop on Advancing 2012



7

Pediatric Therapeutics,

3. Professional societies, elected positions.

American Psychiatric Association 1983-Present

Workgroup on Substance Abuse Practice Guidelines 1992-1995

Council on Addiction Psychiatry 2010-Present

American Academy of Child and Adolescent Psychiatry 1984-Present

Substance Abuse Committee 1991-1998

Workgroup on Quality Issues 1996-Present

Co-Chair, Workgroup on Quality Issues 2004-Present

Pediatric Psychopharmacology Initiative (PPI) 2006-present

E-AACAP Advisory Group 2007-2011

American Academy of Addiction Psychiatry 1989

American Society of Addiction Medicine 1992-2005

International Society on Research in Child and 1997-Present

Adolescent Psychopathology

Research Society on Alcoholism 1999-Present

Texas Society of Child and Adolescent Psychiatry 2010-Present

Harris County Medical Society 2011-Present

4. Invited lectures, presentations, research seminars: National, International

October 19, 1989 Bukstein O, Kaminer Y: Administrative and treatment issues in a program for

dual-diagnosis adolescents. The 36th Annual Meeting of the American

Academy of Child and Adolescent Psychiatry, New York, NY.

October 19, 1991 Bukstein OG: New Diagnostic Instruments for Adolescent Chemical

Dependency Assessment, Symposium, Annual Meeting of American Academy

of Child and Adolescent Psychiatry, San Francisco, CA.

October 18, 1995 Bukstein OG: Mood Disorders and Adolescent Substance Use Disorders.

Institute sponsored by NIDA, Annual Meeting of the American Academy of

Child and Adolescent Psychiatry, New Orleans, LA.

October 19, 1995 Bukstein OG, Clark DB, Pollock N, Lynch K: Mood, Conduct Disorder and

Substance Abuse in Adolescents. Symposium presented at the Annual Meeting

of the American Academy of Child and Adolescent Psychiatry, New Orleans,

LA.

October 25, 1996 Bukstein OG, Clark DB, Pollock N, Lynch K: Adolescents with Alcohol and

Other Substance Use Disorders Only: A Description and Comparison with

Adolescents with Comorbidity, Symposium presented at Annual Meeting of the

American Academy of Child and Adolescent Psychiatry, Philadelphia, PA

October 27, 2001 Bukstein OG, Clark DB, Kelly T, Lynch K: The Effects of Psychiatric

Comorbidity on Substance Use Variables In Adolescents With Alcohol Use

Disorders. Symposium, Annual Meeting of American Academy of Child and

Adolescent Psychiatry, Honolulu, Hawaii.

April 30, 2001 Bukstein OG: Treatment Innovations in Adolescent Substance Use Disorders,

Symposia, Promised Childhood Congress, Israeli Association of Child and

Adolescent Psychiatry, Tel Aviv, Israel

May 3, 2001 Bukstein OG: Pharmacotherapy of Mood Disorders and Substance Use

Disorders in Adolescents, Symposia, Promised Childhood Congress, Israeli

Association of Child and Adolescent Psychiatry, Tel Aviv, Israel

October 24, 2002 Bukstein OG, Cornelius J, Mezzich A, Wood S: Major Depressive Disorder in

Female Adolescents With and Without Alcohol Use Disorder, Symposium,



8

Annual Meeting of American Academy of Child and Adolescent Psychiatry, San

Francisco, CA

October 25, 2002 Bukstein OG, Molina B. Clark DB, Wood, S: Substance Abuse Comorbidity with

ADHD, Symposium, Annual Meeting of American Academy of Child and

Adolescent Psychiatry, San Francisco, CA

October 18, 2003 Bukstein OG: Recent Advances in Adolescents Substance Use Disorders,

Symposium, Annual Meeting of American Academy of Child and Adolescent

Psychiatry, Miami, FL

October 23, 2004 Bukstein OG, Clark DB, Cornelius J, Mezzich A, Wood S: ADHD and CD

Symptoms Affect the Course of Alcohol Use Disorders in Adolescents,

Symposium, Annual Meeting of American Academy of Child and Adolescent

Psychiatry, Washington, DC

March 23, 2005 Bukstein OG: Psychopharmacology of Adolescent Substance Use Disorders,

Symposium presented at 2005 Joint Meeting on Adolescent Treatment

Effectiveness, DHHS, Washington, DC

October 22, 2005 Bukstein OG: Recent Findings in Adolescent Substance Abuse Treatment

Research Symposium. Annual Meeting of American Academy of Child and

Adolescent Psychiatry, Toronto, Ontario Canada

October 27, 2006 Bukstein OG, Christian N, Baker J, Molina BS: ADHD in a Juvenile Detention

Center Population Symposium. Annual Meeting of American Academy of Child

and Adolescent Psychiatry, San Diego, CA,

October 28, 2006 Bukstein OG, Molina BS, Kelly T, Wood S: Patterns of Delinquent Behavior in

Adolescents with Alcohol Use Disorders. Symposium. Annual Meeting of

American Academy of Child and Adolescent Psychiatry, San Diego, CA

November 2006 Molina BSG, Flory K, Bukstein O, Greiner A, Baker J, Evans SW: Feasibility

of a randomized study of the CHP model of treatment for ADHD in a large

Pittsburgh middle school. In S.W. Evans (Chair), School-based treatment of

middle school aged children with ADHD. Symposium presentation at the

Annual Meeting of the Association for Behavioral and Cognitive Therapy,

Chicago, IL.

October 27, 2007 Bukstein OG: Substance Use Disorders among Adolescents with Bipolar

Disorder. Symposium. Annual Meeting of American Academy of Child and

Adolescent Psychiatry, Boston, MA.

May 5, 2008 Bukstein OG: Mental Health and Substance Use Treatment Utilization in

Adolescents with Substance Use Disorders. Symposium. Annual Meeting of the

American Psychiatric Association, Washington, DC.

October 29, 2008 Bukstein OG: Depression and Substance Use Disorders in Adolescents,

Institute. Annual Meeting of American Academy of Child and Adolescent

Psychiatry, Chicago, LI.

November 1, 2008 Bukstein, OG: Assessment, Coordination of Care, and clinical considerations in

the Management of Substance Use Disorders in Adolescents. Annual Meeting of

American Academy of Child and Adolescent Psychiatry, Chicago, IL.

June 20, 2009 Bukstein, OG: Depression and Alcohol Use in Adolescents: A Longitudinal

Examination. Symposium Meeting of the International Society for Research in

Child and Adolescent Psychopathology. Seattle, WA.

October 29, 2009 Bukstein, OG: Medication Acceptability and Effectiveness in Oppositional

Defiant Disorder/Conduct Disorder Children with Comorbid ADHD.

Symposium. Annual Meeting of American Academy of Child and Adolescent

Psychiatry. Honolulu, HI

October 29, 2009 Bukstein, OG: Current Perspectives on Integrated Psychosocial Interventions

for Adolescents with Comorbid Mood-Related and Substance Use Disorders.



9

Symposium. Annual Meeting of American Academy of Child and Adolescent

Psychiatry. Honolulu, HI

October 30, 2010 Bukstein, OG: Assessment and Treatment of Alcohol and Drug Problems in

College Symposium. Annual Meeting of American Academy of Child and

Adolescent Psychiatry. New York City, NY

October 20, 2011 Bukstein, OG Substance Use Disorders in Adolescents. AACAP Life Long

Learning Institute, Annual Meeting of American Academy of Child and

Adolescent Psychiatry. Toronto, ON, Canada

February 10, 2012 Bukstein, OG Substance Use Disorders in Adolescents. AACAP Life Long

Learning Institute, Sand Diego, CA.

October 28, 2012 Bukstein, OG: Assessment and Treatment of Alcohol and Drug Problems in

College Symposium. Annual Meeting of American Academy of Child and

Adolescent Psychiatry. San Francisco, CA

October 27 , 2013 Treatment of Severe Child Aggression: TOSCA Network. Symposium. Annual

Meeting of American Academy of Child and Adolescent Psychiatry. Orlando,

FL.

Invited Lectures:

October 26, 1990 Patterns of Affective Comorbidity in a Clinical Population of Adolescent

Substance Abusers, NIMH Conference on Dual Diagnosis, Rockville, MD.

July 14, 1991 Adolescent Conduct Disorder and Substance Abuse, Expert Panel Conference,

Value Behavioral Health, Santa Monica, CA.

March 28, 1996 Risk Factors for Substance Use Disorders in Children and Adolescents. Hospital

for Sick Children, Toronto, Canada.

March 29, 1996 Mood and Conduct Disorders in Adolescents with Substance Use Disorders.

Clarke Institute and Addiction Research Foundation, Toronto, Canada.

November 5-6, 1996 Adolescent Substance Abuse, Mid-Missouri Mental Health Center, University of

Missouri School of Medicine, Columbia, MO.

May 15, 1997 Adolescent Substance Abusers and Coexisting Psychiatric Disorders, Annual

Meeting of Missouri Chemical Dependency Professionals, Osage Beach, MO.

May 12, 1998 Comorbidity in Adolescents with Substance Use Disorders, Comprehensive

Drug and Alcohol Program of Fairfax County, Fairfax, VA.

November 3, 4, 1998 Comorbidity in Adolescents with Substance Use Disorders, Department of

Drug and Alcohol, State of Vermont, Burlington, VT.

November 19, 1998 Salient Variables for Adolescent Treatment Research, National Institute on

Alcohol Abuse and Alcoholism, Bethesda, MD.

March 20, 1999 Treatment Update: What’s New in the Treatment of Adolescent Substance

Abuse, Indiana Psychiatric Society, Indianapolis, IN.

June 2, 2000 Dual Diagnosis in Adolescents, Delaware Department of Public Welfare, Dover,

DE.

February 5, 2001 Attention Deficit Hyperactivity and Substance Use Disorders, Grand Rounds,

Department of Psychiatry, University of Miami, FL.

October 12, 2001 Psychopharmacology of Adolescents With Substance Use Disorders: Using

Diagnosis Specific Treatments. Treating adolescent substance abuse; The state

of the science. A NIDA sponsored conference. Center for Treatment Research

on Adolescent Drug Abuse, University of Miami. Coral Gables, FL.

January 8, 2002 Attention Deficit Hyperactivity Disorder and Substance Abuse in Adolescents:

Risk Factors and Treatment Targets. Fisher-Cummings Visiting Professorship in

Substance Abuse, Children’s Hospital of Michigan, Detroit, MI.

August 1, 2003 Adolescent Substance Abuse and ADHD, Grand Rounds, Department of Psychiatry,

University of South Florida, Tampa, FL.



10

March 4, 2004 Substance Abuse Comorbidity with ADHD. Grand Rounds, University of

Minnesota, Minneapolis, MN.

September 30, 2004 Adolescent Substance Use Disorders and Comorbidity, Annual Kentucky Mental

Health Institute, Louisville, KY.

February 25, 2005 Adolescent Substance Use Disorders, Annual Review, American Academy of

Addiction Psychiatry, Atlanta, GA.

October 18, 2005 Clinical Practice Guidelines, Research Forum. Annual Meeting of American

Academy of Child and Adolescent Psychiatry, Toronto, Ontario, Canada.

April 13, 2006 ADHD Medical Safety, Grand Rounds, Allegheny General Hospital, Pittsburgh,

PA..

November 19, 2007 Does Dual Diagnosis Matter?, Children’s Hospital Research Institute. Children’s

Hospital of Columbus, Columbus, OH.

November 20, 2007 What Really is Dual Diagnosis Treatment for Adolescents? Alcohol, Drug and

Mental Health Board and The Ohio State University’s Lecture Series. Alcohol,

Drug and Mental Health Board of Franklin County, Columbus, OH.

July 28, 2010 Best Practices for the Assessment and Treatment of Children and Adolescents

with Substance Use Disorders. Annual Meeting of the Texas Society of Child

and Adolescent Psychiatry, Galveston, TX

March 9, 2011 The Development of Practice Parameters for the Assessment and Treatment of

Children and Adolescents with Substance Use Disorders, Grand Rounds, Boston

Children’s Hospital, Boston, MA

January 20, 2012 Treatment of Adolescent Substance Use Disorders: State of the Science, Grand

Rounds, Department of Psychiatry, Case Western Reserve University, Cleveland,

OH

May 3, 2013 Adolescent Dual Disorders: Does It Make a Difference. Florida International

University, Miami, FL

November 20, 2013 Treatment of Severe Child Aggression: Findings from the TOSCA Network.

Grand Rounds. University of Texas Health Science Center. Houston, TX

C. Publications

Full Papers: Refereed Articles:

1. Bukstein OG, Brent DA, Kaminer Y: Comorbidity of substance abuse and other psychiatric

disorders in adolescents. Am J Psychiatry, 146:1131-1141, 1989.

2. Kaminer Y, Bukstein OG: Adolescent Chemical Use and Dependency: Current issues in

epidemiology treatment and prevention. ACTA Psychiatrica Scand, Vol. 79:415-424, 1989.

3. Brent DA, Zelenak JP, Bukstein OG, Brown RV: Reliability and validity of the structured

interview for personality disorders in adolescents. J Am Acad Child Adol Psychiatry, 29:349-

354, 1990.

4. Tarter RE, Laird B, Kabene M, Bukstein OG, Kaminer Y: Drug abuse severity in adolescents

is associated with magnitude of deviation in temperament traits. Br J Addict, 85:1501-1504,

1990.

5. Kaminer Y, Bukstein OG, Tarter RE: The Teen-Addiction Severity Index: Rationale and

reliability. Int J Addictions, 26:219-226, 1991.

6. Arria A, Mezzich A, Tarter R, Bukstein O, Van Hasselt V, Van Thiel D: Evidence for early

onset liver injury in alcohol abusing adolescents. Alcohol Clin Exp Res, 15:371, 1991.

7. Tarter RE, Laird S, Bukstein O: Multivariate comparison of adolescent offspring of substance

abuse parents: Community and treatment samples. J Subst Abuse, 3:301-306, 1991.

8. Bukstein OG, Glancy LJ, Kaminer Y: Patterns of affective comorbidity in a clinical

population of dually-diagnosed adolescent substance abusers. J Am Acad Child Adol

Psychiatry, 6:1041-1045, 1992.



11

9. Kaminer Y, Tarter RE, Bukstein OG, Kabene M: Comparison between treatment completers

and noncompleters among dually diagnosed substance abusing adolescents. J Am Acad Child

Adol Psychiatry, 31:1046-1049, 1992.

10. Tarter RE, Laird SB, Bukstein OG, Kaminer Y: Validation of the adolescent drug use

screening inventory: Preliminary findings. Psychol Addict Behav, 6:233-236, 1992.

11. Van Hasselt VB, Ammerman RT, Glancy LJ, Bukstein OG: Maltreatment in psychiatrically

hospitalized dually-diagnosed adolescent substance abusers. J Am Acad Child Adol

Psychiatry, 31:868-874, 1992.

12. Van Hasselt VB, Hersen M, Null JA, Ammerman RT, Bukstein OG, McGillivray J, Hunter A:

Drug abuse prevention for high-risk African-American children and their families: A review

and model program. Addict Behav, 18:213-234, 1993.

13. Bukstein OG, Brent DA, Perper JA, Moritz G, Baugher M, Schweers J, Roth C, Balach L:

Risk factors for completed suicide among adolescents with a lifetime history of substance

abuse: A case-control study. Acta Psychiatrica Scandinavica, 88:403-408, 1993.

14. Van Hasselt VB, Null JA, Kempton T, Bukstein OG: Social skills and depression in

adolescent substance abusers. Addict Behav, 18:9-18, 1993.

15. Martin CS, Arria AM, Mezzich AC, Bukstein OG: Patterns of polydrug use in adolescent

alcohol abusers. Am J Drug Alcohol Abuse, 19:511-521, 1993.

16. Bukstein OG: The treatment of adolescent alcohol abuse and dependence. Alcohol Health

and Research World, 18:296-301, 1994.

17. Bukstein OG, Kaminer Y: The nosology of adolescent substance abuse. Am J Addict, 3:1-13,

1994.

18. Messer SC, Kempton T, Van Hasselt VB, Null JA, Bukstein OG:. Cognitive distortions and

adolescent affective disorder: Validation of the CNCEQ in an inpatient sample. Behav Modif,

18:339-351, 1994.

19. Kempton T, Van Hasselt VB, Bukstein OG, Null JA: Cognitive distortions and psychiatric

diagnosis in dually diagnosed adolescents. J Am Acad Child Adol Psychiatry, 33:217-2322,

1994.

20. Leonard HL, Topol D, Bukstein O, Hindmarsh D, Allen AJ, Swedo SE: Clonazepam as an

augmenting agent in the treatment of childhood-onset Obsessive-Compulsive Disorder. J Am

Acad Child Adol Psychiatry, 33:792-794, 1994.

21. Arria AM, Dohey MA, Mezzich AC, Bukstein OG: Self-reported health problems and

physical symptomology in adolescent alcohol abusers. J Adol Health, 16:226-231, 1995.

22. Bukstein OG: Influences on the risk and course of substance use and abuse in adolescents.

Current Opinion in Psychiatry, 8:218-221, 1995.

23. Clark DB, Bukstein OG, Smith MG, Kaczynski NA, Mezzich AC, Donovan JE: Identifying

anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. Psychiatric

Services, 46:618-620, 1995.

24. Martin CS, Kaczynski NA, Maisto SA, Bukstein OG, Moss HB: Patterns of alcohol abuse

and dependence symptoms in adolescent drinkers. J Stud Alcohol Drugs, 56:672-680, 1995.

25. Bukstein OG: Aggression, violence and adolescent substance abuse. Child Adolesc Psychiatr

Clin N Am, 5:93-109, 1996.

26. Clark DB, Pollack N, Bukstein OG, Mezzich AC, Bromberger JT, Donovan JE: Gender and

comorbid psychopathology in adolescents with alcohol dependence. J Am Acad Child Adol

Psychiatry, 36:1195-1203, 1997.

27. American Academy of Child and Adolescent Psychiatry, Primary author: Bukstein OG:

Practice parameters for the assessment and treatment of children and adolescents with

substance use disorders. J Am Acad Child Adol Psychiatry, 36(Supl):140S-156S, 1997.

28. Dulcan, M, Dunne, JE, Ayres, W, Arnold, V, Benson, RS, Bernet, W, Bukstein, O, Kinlan, J,

Leonard, H, Licamele, W, McClellan, J, Sloan, LE, Miles, CM. Practice parameters for the

assessment and treatment of children, adolescents, and adults with Attention-



12

Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 36(Supl):85S-121S,

1997.


Summary of the practice parameters for the assessment and treatment of children and

adolescents with substance use disorders. J Am Acad Child Adol Psychiatry, 37:122-126,

1998.

30. Smith B, Pelham WE, Evan S, Gnagy E, Molina B, Bukstein OG, Grenier A, Myak C,

Presnell M, Willoughby M: Dosage effects of methylphenidate on the social behavior of

adolescents with attention-deficit hyperactivity disorder. Exper Clin Psychopharmacol, 6:187-

204, 1998.

31. Bukstein OG, Kolko DJ: The effects of methylphenidate on aggressive, urban children with

attention-hyperactivity disorder. J Clin Child Psychol, 27:340-351, 1998.

32. Clark DB, Bukstein OG: Psychopathology in adolescent alcohol abuse and dependence.

Alcohol Health & Research World, 22:117-121, 1998.

33. Kolko D, Bukstein OG, Barron J: Methylphenidate and behavior modification in children with

ADHD and comorbid ODD or CD: Main and incremental effects across settings. J Am Acad

Child Adolesc Psychiatry, 38:578-586, 1999.

34. Bukstein OG: Disruptive behavior disorders and substance use disorders in adolescents.

Journal of Psychoactive Drugs, 32:67-80, 2000.

35. Martin CS, Pollock NK, Bukstein OG, Lynch KG: Inter-rater reliability of the SCID alcohol

and substance use disorders section among adolescents. Drug Alcohol Depend, 59:173-176,

2000.

36. Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro

S, Bukstein OG, Myack C: Behavioral versus behavioral and pharmacological treatment in

ADHD children attending a summer treatment program. J Abn Child Psychology, 28:507-526,

2000.

37. Swanson J, Greenhill L, Pelham W, Wilen T, Wolraich M, Abikoff H, Atkins M, August G,

Biederman J, Bukstein OG, et al.: Initiating Concerta (OROS methylphenidate) q d in

children with attention deficit hyperactivity disorder. J Clin Research, 3:59-76, 2000.

38. Cornelius JR, Bukstein OG, Birmaher B, Salloum IM, Lynch K, Pollack NK, Gershon S,

Clark D: Fluoxetine in adolescents with major depression and an alcohol use disorder; an open

label trial. Addict Behav, 26:735-739, 2001.

39. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold E., Abikoff

HB, Bukstein OG, et al.: Impairment and Deportment responses to different methylphenidate

doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry,

40:180-187, 2001.

40. Viltiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al.:

Methylphenidate dosage for children with ADHD over time under controlled conditions:

Lessons from the MTA. J Am Acad Child Adolesc Psychiatry, 40:188-196, 2001

41. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M,

McBurnett K, Bukstein O, August G on behalf of the Concerta Study Group: Randomized,

controlled trial of OROS methylphenidate once a day in children with Attention-

Deficit/Hyperactivity Disorder. Pediatrics, 108:883-892, 2001.

42. McClellan J, Werry J, Bernet W, Arnold V, Beitchman J, Benson S, Bukstein O, Kinlan J,

Rue D, Shaw J: Practice parameter for the assessment and treatment of children and

adolescents with schizophrenia. J American Acad Child Adolesc Psychiatry, 40(Suppl):4S-

23S, 2001.

43. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy E M, Greiner AR, Altenderfer L,

Baron-Myak C: Dose-response effects of methylphenidate on ecologically valid measures of

academic performance and classroom behavior in adolescents with ADHD. Exp Clin

Psychopharmacol, 9:163-175, 2001.



13

44. Cornelius JR, Clark DB, Salloum IM, Bukstein OG, Kelly TM: Management of suicidal

behavior in alcoholism. Clinical Neuroscience Research, 1:381-386, 2001.

45. Molina BSG., Bukstein OG, Lynch K: Attention-Deficit/Hyperactivity Disorder and Conduct

Disorder symptomatology in adolescents with Alcohol Use Disorder. Psychol Addict Behav,

16:161-164, 2002.

46. Clark DB, Bukstein OG, Cornelius J: Alcohol use disorders in adolescents. Pediatr Drugs,

4:493-502, 2002.

47. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Clark DB: Psychiatric

disorders among older adolescents treated in emergency departments on weekends: A

comparison with a matched community sample. J Studies Alcohol, 64:616-622, 2003.

48. Clark DB, Wood DS, Cornelius JR, Bukstein OG, Martin CS: Clinical Practices in the

Pharmacological treatment of Comorbid Psychopathology in Adolescents with Alcohol Use

Disorders. J Subst Abuse Treat, 25:293-295, 2003.

49. Cornelius JR, Bukstein OG, Salloum IM, Kelly TM, Wood DS, Clark DB: Fluoxetine in

depressed AUD adolescents: A one-year follow-up evaluation. J Child Adolesc

Psychopharmacol, 14:33-38, 2004.

50. Cornelius JR, Clark DB, Salloum IM, Bukstein OG, Kelly TM: Interventions in Suicidal

Alcoholics. Alcohol Clin Exp Res, 28(5 Suppl):1S-8S, 2004.

51. Cornelius JR, Maisto SA, Martin CS, Bukstein OG, Salloum IM, Daley DC, Wood DS, Clark

DB: Major depression associated with earlier alcohol relapse in treated teens with AUD.

Addict Behav, 26:1035-1038, 2004.

52. Bukstein OG: Satisfaction with Treatment for Attention-Deficit/Hyperactivity Disorder.

American Journal of Managed Care, 10:S107-116, 2004.

53. Kelly TM, Bukstein OG: Evaluation and Treatment of Substance Use Problems among

Adolescents in Emergency Departments. Clin Ped Emerg Med, 5:164-172, 2004

54. Bukstein OG, Winters K: Salient variables for treatment research of adolescent alcohol and

other substance use disorders. Addiction, 99 (Suppl):23S–37S, 2004.

55. Bukstein OG, Trunzo AC: Alcohol use disorders in adolescents. Minerva Pediatr, 57:7-20,

2005.

56. Chacko A, Pelham WE, Gnagy E, Greiner A, Vallano G, Bukstein O, Rancurello M: Stimulant

Medication Effects in a Summer Treatment Program Among Young Children With Attention-

Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 44:249-257, 2005.


Practice parameters for the assessment and treatment of children and adolescents with

substance use disorders. J Am Acad Child Adol Psychiatry, 44:609-621, 2005.

58. Cornelius JR, Clark DB, Bukstein OG, Kelly TM, Salloum IM, Wood DS: Fluoxetine in

adolescents with comorbid major depression and an alcohol use disorder: A 3-year follow-up

study. Addict Behav, 30:807-814, 2005.

59. Bukstein OG, Cornelius J, Trunzo AC, Kelly TM, Wood DS. Clinical Predictors of Treatment

in a Population of Adolescents with Alcohol Use Disorders. Addict Behav, 30:1663-1673,

2005.

60. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge, TR, Kinnane JM: Alcohol use

disorder symptoms and risk-taking behavior as predictors of alcohol-related medical events

among young adults treated in emergency departments. Addict Behav, 30:1674-1689, 2005.

61. Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA: Acute phase and

five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid

substance use disorder: A review. Addict Behav, 30:1824-1833, 2005.

62. Galanter CA, Pager DL, Davies M, Li W, Carlson GA, Abikoff, HB, Arnold LE, Bukstein

OG, Pelham W, Elliot GR, Hinshaw S, Epstein JN, Wells K, Hechtman L, Newcorn JH,

Greenhill L, Wigal T, Swanson JM, Jensen PS: ADHD and manic symptoms: Diagnostic and

treatment implications, Clinical Neuroscience Research, 5:283-295, 2005.



14

63. Bukstein OG, Cornelius J, Kelly TM, Wood DS: Bipolar Disorder in a Population of

Adolescents with Alcohol Use Disorders. Journal of Dual Disorders, 2:59-72, 2005.

64. Wilens T, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners

CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P,

Bloom L, Zimmerman BA, Gu J, Cooper K, Lynch JM: A Multisite, Controlled Trial of

OROS® Methylphenidate (CONCERTA®) in the Treatment of Adolescents with Attention-

Deficit/Hyperactivity Disorder. Archives of Pediatrics and Adolescent Medicine, 160:82-90,

2006.

65. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M: Once-

daily OROS methylphenidate is safe and well tolerated in adolescents with attention-

deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 16(2):351–356, 2006.

66. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Pettegrew JW,

Keshavan MS, Bukstein OG: Regionally specific alterations in membrane phospholipids in

children with ADHD: An in vivo31

P spectroscopy study. Psychiatry Research: Neuroimaging,

148:217–221, 2006.

67. Szobot C, Rohde L, Bukstein O, Molina B, Martins C, Ruaro P, Pechansky F: Is Attention-

Deficit/Hyperactivity Disorder associated with illicit Substance Use Disorders in male

adolescents? A community-based case-control study. Addiction, 102:1122–1130, 2007.

68. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton JD, Kremer C,

Kratochvil CJ: AACAP 2005 Research Forum: Speeding The Adoption Of Evidence-Based

Practice In Pediatric Psychiatry. J Am Acad Child Adolesc Psychiatry, 46:1098-1110, 2007.

69. Kolko DJ, Baumann BL, Bukstein OG, Brown, EJ: Internalizing symptoms and affective

reactivity in relation to the severity of aggression in clinically referred, behavior-disordered

children. Journal of Child and Family Studies, 16:745-759, 2007.

70. Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP, The CAT

Study Team: Clonidine for Attention-Deficit/Hyperactivity Disorder: I. Efficacy and

tolerability outcomes. J Am Acad Child Adolesc Psychiatry, 47:180-188, 2008.

71. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Palumbo D,

Harris P, Sallee FR, The CAT Study Team: Clonidine for Attention-Deficit/Hyperactivity

Disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc

Psychiatry, 47:189-198, 2008.

72. Kolko DJ, Dorn LD, Bukstein OG, Burke J: Clinically Referred ODD children with or without

CD and healthy controls: Comparisons across contextual domains. Journal of Child and Family

Studies, Online First™, 2008.

73. Szobot CM, Bukstein O: Attention deficit hyperactivity disorder and substance use disorders.

Child Adolesc Psychiatric Clin N Am, 17:309-323, 2008.

74. Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T. Walcher M, Bukstein O, Pechansky F:

A randomized crossover clinical study showing that methylphenidate-SODAS improves

Attention-Deficit/ Hyperactivity Disorder symptoms in adolescents with Substance Use

Disorder: a randomized crossover clinical trial. The Brazilian Journal of Medical and

Biological Research, 41: 250-257, 2008.

75. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD: A

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Methylphenidate

Transdermal System in Pediatric Patients with ADHD. J Clin Psychiatry, 69:149–159, 2008.

76. Marshal MP, Friedman MS, Stall R, King KM, Miles J, Gold MA, Bukstein OG, Morse JQ:

Sexual orientation and adolescent substance use: A meta-analysis and methodological review.

Addiction, 103:546–556, 2008

77. Cornelius JR, Bukstein OG, Clark DB, Matta JK, Salloum IM, Wood DS: Fluoxetine Trial for

the Cannabis-Related Symptoms of Comorbid Adolescents. Journal of Drug Addiction,

Education and Eradication, 3:223-228, 2008.

78. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Keshavan MS, Bukstein

OG, Pettegrew JW: Evidence of Developmental Alterations in Cortical and Subcortical Regions


http://www.scirus.com/srsapp/sciruslink?src=sd&url=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%3F_ob%3DGatewayURL%26_origin%3DScienceSearch%26_method%3DcitationSearch%26_piikey%3DS0925492706001260%26_version%3D1%26_returnURL%3Dhttp%253A%252F%252Fwww.scirus.com%252Fsrsapp%252Fsearch%253Fq%253D%2528au%25253Astanley%252BOR%252Bau%25253Aja%2529%252BAND%252B%2528issn%25253A09254927%2529%2526ds%253Dbls%2526ds%253Dsd%2526ds%253Dmps%2526ds%253Dcps%2526ds%253Dcpp%2526p%253D0%2526drill%253Dyes%26md5%3D3bffde1f3c2192902330093390926592

http://www.scirus.com/srsapp/sciruslink?src=sd&url=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%3F_ob%3DGatewayURL%26_origin%3DScienceSearch%26_method%3DcitationSearch%26_piikey%3DS0925492706001260%26_version%3D1%26_returnURL%3Dhttp%253A%252F%252Fwww.scirus.com%252Fsrsapp%252Fsearch%253Fq%253D%2528au%25253Astanley%252BOR%252Bau%25253Aja%2529%252BAND%252B%2528issn%25253A09254927%2529%2526ds%253Dbls%2526ds%253Dsd%2526ds%253Dmps%2526ds%253Dcps%2526ds%253Dcpp%2526p%253D0%2526drill%253Dyes%26md5%3D3bffde1f3c2192902330093390926592


15

of Children With Attention-Deficit/Hyperactivity Disorder: A Multivoxel In Vivo Phosphorus

31 Spectroscopy Study. Arch Gen Psychiatry, 65:1419-1428, 2008

79. Molina BSG, Flory K, Bukstein OG, Greiner AR, Baker JL, Krug V, Evans S: Feasibility and

preliminary efficacy of an after school program for middle schoolers with ADHD: A

randomized trial in a large public middle school. J Atten Disord, 12:207 – 217, 2008.

80. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL: Effects of Once-

Daily Oral and Transdermal Methylphenidate on Sleep Behavior of Children with ADHD. J

Atten Disord, 12:308-315, 2009.

81. Dorn LD, Kolko DJ, Susman EJ, Huang B, Stein H, Music E, BuksteinOG: Salivary gonadal

and adrenal hormone differences in boys and girls with and without disruptive behavior

disorders: Contextual variants. Biological Psychology, 81:31-39, 2009.

82. Kolko DJ, Dorn LD, Bukstein OG, Pardini J, Holden EA, Hart J: Community vs. Clinic-Based

Modular Treatment of Children with Early-Onset ODD or CD: A Clinical Trial with 3-Year

Follow-Up. J Abnorm Child Psychol, 37:591–609, 2009.

83. Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT, Vitiello B, Bukstein O,

Stanley B, Posner K, Kennard BD, Cwik MF, Wagner A, Coffey B, March JS, Riddle M,

Goldstein T, Curry J, Barnett S, Capasso L, Zelazny J, Hughes J, Shen SA, Gugga SS, Tuner

JB: The Treatment of Adolescent Suicide Attempters Study (TASA): Predictors of suicide

events in an open treatment trial. J Am Acad Child Adolesc Psychiatry, 48:987-996, 2009.

84. Vitiello B, Brent DA, Greenhill LL, Emslie G, Wells K, Walkup JT, Stanley B, Bukstein O,

Kennard BD, Compton S, Coffey B, Cwik MF, Posner K, Wagner A, March JS, Riddle M,

Goldstein T, Curry J, Capasso L, Mayes T, Shen SA, Gugga SS, Turner JB, Barnett S, Zelazny

J: Depressive symptoms and clinical status during the Treatment of Adolescent Suicide

Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry, 48:997-1004, 2009.

83. Kelly TM, Donovan JE, Chung T, Bukstein OG, Cornelius JR: Brief Screens for Detecting

Alcohol Use Disorder Among 18-20 Year Old Young Adults in Emergency Departments:

Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale.

Addictive Behaviors, 34: 668-674, 2009.

84. Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB: Double-Blind

placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an

alcohol use disorder. Addictive Behaviors, 34:905-909, 2009.

85. Bukstein O, Arnold LE, Landgraf J, Hodgkins P. Does switching from oral extended-release

methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life

and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child

Adolesc Psychiatry Ment Health, 3(1):39-51, 2009.

86. Cannon M, Pelham WH, Salee, FR, Palumbo DR, Bukstein, O, Daviss WB Effects of

clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity

disorder. Journal of Child & Adolescent Psychopharmacology. 19(5):511-7, 2009.

86. Arnold L, Bozzolo D, Hodgkins P, McKay M, Beckett-Thurman L, Greenbaum M, Bukstein O,

Patel A. Switching from oral extended-release methylphenidate to the methylphenidate

transdermal system: continued attention-deficit/hyperactivity disorder symptom control and

tolerability after abrupt conversion. Current Medical Research & Opinion. 26(1):129-137, 2010.

87. Goldstein BI, Bukstein OG: Comorbid Substance Use Disorders among Youth with Bipolar

Disorder: Opportunities for Early Identification and Prevention. J Clin Psychiatry.

Mar;71(3):348-58, 2010.

88. Bukstein OG, Horner MS. Management of the adolescent with substance use disorders and

comorbid psychopathology. Child Adolesc Psychiatr Clin N Am. 19(3):609-23, 2010.

89. Findling RL. Wigal SB. Bukstein OG. Boellner SW. Abikoff HB, Turnbow JM. Civil R.

Long-term tolerability of the methylphenidate transdermal system in pediatric attention-

deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled,

phase III extension of four clinical trials. Clinical Therapeutics. 31(8):1844-55, 2009.


http://ovidsp.tx.ovid.com.ezproxyhost.library.tmc.edu/sp-3.3.1a/ovidweb.cgi?&S=EIBNFPPMKMDDBIPINCCLGCJCMPBJAA00&Complete+Reference=S.sh.15%7c10%7c1



http://www.ncbi.nlm.nih.gov/pubmed/20682224






16

90. Jack R. Cornelius, JR, Bukstein OG, Douaihy AB, Clark, DB, Chung TA, Daley DC, Wood

DS, Brown, SJ. Double-blind fluoxetine trial in comorbid MDD–CUD youth and young adults.

Drug and Alcohol Dependence 112 39–45, 2010.

91. Bukstein OG. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review.

Postgrad Med. 122(5):69-77, 2010.

92. Demidovich, M. Kolko, DJ, Bukstein, OG, Hart J, Journal of Child and Adolescent

Psychopharmacology 21: 57-66, 2011.

93. Farmer CA, Arnold LE, Bukstein OG, Findling RL, Gadow KD, Li X, Butter EM, Aman MG.

The Treatment of Severe Child Aggression (TOSCA) Study: Design Challenges. Child Adolesc

Psychiatry Ment Health 5(1): 36,

94. Cornelius JR, Douaihy A, Bukstein OG, Daley DC, Wood SD, Kelly TM, Salloum IM.

Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a

treatment trial of comorbid MDD/AUD adolescents. Addictive Behaviors. 36(8): 843-848, 2011.

95. Dorn LD, Kolko DJ, Shenk CE, Susman EJ, Bukstein O. Influence of treatment for disruptive

behavior disorders on adrenal and gonadal hormones in youth. Journal of Clinical Child and

Adolescent Psychology. 40(4): 562-571, 2011.

96. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K,

Youcha S, A controlled trial of extended-release guanfacine and psychostimulants for attention-

deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 51(1):74-85, 2012.

97. Bukstein OG, Head J, Guanfacine ER for the treatment of adolescent attention-

deficit/hyperactivity disorder. Expert Opinion. Posted online on September 7, 2012.

(doi:10.1517/14656566.2012.721778)

98. Pelham WE, Meichenbaum D, Smith B, Sibley MH, Gnagy E, & Bukstein O. (in press). The

Effect of MPH on Parent-Directed Conflict Behavior in Adolescents with ADHD. Journal of

Attention Disorders.

99. Pearson DA, Santos CW, Aman MG, Arnold LE, Casat CD, Mansour R, Lane DM, Loveland KA,

Bukstein OG, Jerger SW, Factor P, Vanwoerden S, Perez E, & Cleveland LA (in press). Effects

of extended release methylphenidate treatment on ratings of ADHD and associated behavior in

children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent

Psychopharmacology, 23(5): 337-351 2013.

100. Pelham, W.E., Gnagy, E.M., Sibley, M.H., Kipp, H.L., Smith, B.H., Evans, S.W., & Bukstein, O.

(in press). Attributions and Perception of Methylphenidate Effects in Adolescents with ADHD.

Journal of Attention Disorders , doi: 10.1177/1087054713493320

101. Goldstein BI, Goldstein TR, Collinger KA, Axelson DA, Bukstein OG, Birmaher B, Millowiitz

DJ (in press) Treatment Development and Feasibility Study of Family-Focused Treatment for

Adolescents with Bipolar Disorder and Comorbid Substance Use Disorders Journal of Psychiatric

Practice.

102. Aman, M.G., Bukstein, O.G., Gadow, K.D., Arnold, L.E., Molina, B.S.G., McNamara, N.K., Rundberg-Rivera, V., Li, X., Kipp, H., Schneider, J., Butter, E.M., Baker, J., Sprafkin, J., Rice, R.R., Bangalore, S.S., Farmer, C.A., Austin, A.B., Buchan-Page, K.A., Arradaza, N.V., Hurt, E.A., Grondhuis, S.N., Findling, R.L. (In press). What does risperidone add to stimulant and parent training for severe aggression in child ADHD? Journal of the American Academy of Child and Adolescent Psychiatry.

2. Other Papers: Invited Articles:

1. Bukstein OG: Drug testing in schools: good practice or good politics? Random drug testing of

adolescent students sounds like good commonsense policy--but where's the evidence? Behavioral

Health Management, July, 2004.


http://www.ncbi.nlm.nih.gov.ezproxyhost.library.tmc.edu/pubmed/20861590




http://findarticles.com/p/articles/mi_go1977

http://findarticles.com/p/articles/mi_go1977

http://findarticles.com/p/articles/mi_go1977/is_200407


17

2. Bukstein OG: Dual Disorders in Adolescents (Editorial). Journal of Dual Disorders, 2:7-9,

2006.

3. Bukstein OG: Therapeutic challenges of attention-deficit hyperactivity disorder with substance

use disorders. Expert Review of Neurotherapeutics, 6:541-549, 2007.

4. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML: Changes and challenges: Managing

ADHD in a fast-paced world. J Manag Car Pharm, 13(9 Suppl B):S2-S13; quiz:S14-S16, 2007.

5. Bukstein OG: Substance abuse in patients with Attention-Deficit/Hyperactivity Disorder. The

Medscape Journal of Medicine, 10(1), 2008.

6. Bukstein O: Substance use disorders in adolescents with attention-deficit/hyperactivity disorder.

Adolescent Medicine, 19, 242-53, 2008.

3. Abstracts

4. Books a. Complete books written

Bukstein OG: Adolescent substance abuse: Assessment, treatment and prevention perspectives.

Wiley, New York, 1995.

b. Books edited

Kaminer Y, Bukstein OG: Adolescent Substance Abuse: Psychiatric Comorbidity and High

Risk Behaviors. New York, NY. Routledge Mental Health, 2008.

c. Book chapters

5. Kaminer Y, Bukstein O: Inpatient Behavior Therapy for Dually Diagnosed Chemically

Dependent Adolescents. In, Van Hasselt VB & Kolko DJ (Eds.), Inpatient Behavior Therapy

for Children and Adolescents. (pp. 313-363). New York: Plenum Press, 1992.

6. Bukstein OG: Overview of pharmacological treatment. In, Van Hasselt VB& Hersen M

(Eds.), Handbook of Behavior Therapy and Pharmacotherapy for Children: A comparative

analysis. (pp. 13-32) Needham Heights, MA: Allyn and Bacon, 1993.

7. Bukstein OG, Van Hasselt, VB: Alcohol and drug abuse. In, Bellack AS & Hersen M

(Eds.), Handbook of Behavior Therapy in the Psychiatric Setting. pp 453-476 New York:

Plenum, 1993.

8. Bukstein OG: Substance abuse. In, Hersen M, Ammerman RT & Sisson LA (Eds.),

Handbook of Aggressive and Destructive Behavior in Psychiatric Patients. (pp. 445-468)

New York: Plenum Press, 1994.

9. Windle M, Shope JT, Bukstein OG: Alcohol use. In, DiClemente RJ, Hansen WB & Ponton

LE (Eds.), Handbook of Adolescent Health Risk Behavior. (pp. 115-159). New York:

Plenum Press, 1996.

10. Bukstein OG: The Medical History. In, Hersen M & Van Hasselt VB (Eds.), Basic

Interviewing: A Practical Guide for Counselors and Clinicians. (pp. 87-106). Hillsdale, NJ:

Lawrence Erlbaum Associates, 1998.

11. Bukstein OG, Tarter RE: Adolescent substance use disorders. In, McCracken J, (Ed.),

Textbook of Pediatric Neuropsychiatry. (pp. 595-616). Washington, DC: American

Psychiatric Press, 1998.

12. Kaminer Y, Bukstein OG: Adolescent substance abuse. In, Frances RJ & Miller SI (Eds.),

Clinical Textbook of Addictive Disorders (2nd ed.). (pp. 346-373). New York, NY: Guilford

Press, 1998.

13. Bukstein OG: Adolescent Substance Abuse. In, Sadock BJ & Sadock VA (Eds.),

Comprehensive Textbook of Psychiatry, (7th Edition). (pp. 2932-2938). Baltimore, MD:

Lippincott Williams & Wilkins, 1999.



18

14. Bukstein OG: Substance Abuse. In, Haymean LL, Mahon MM & Turner JR (Eds.), Health

Behavior in childhood and Adolescence. (pp. 178-212) New York, NY: Springer Publishing

Co., 2002.

15. Bukstein OG, Kithas J: Pharmacologicsal Treatment of Substance Use Disorders. In,

Rosenberg, D.A., Davanzo, P.A., Gershon, S. Pharmacotherapy for Child and Adolescent

Psychaitric Disorders, 2nd Edition. (pp. 679-710). New York, NY: Marcal-Dekker, 2002.

16. Barkley, R….Bukstein, O.G… et al.: Consensus statement on ADHD. European Child and

Adolescent Psychiatry, 11(2):96-98, 2002.

17. Bukstein, O.G. Psychopharmacolgy of Disruptive Behavior Disorders In Essau, C.A. (Ed.)

Conduct and Oppositional Defiant Disorders. (pp. 319-358). Mahwah, New Jersey:

Lawrence Erlbaum, 2003.

18. Cornelius JR, Salloum IM, Bukstein OG, Clark DB: Psychaitric comorbidity: Implications

for treatment and clinical research. In, Soares JC, Gershon S (Eds.), Handbook of Medical

Psychiatry. (pp. 553-561). New York, NY: Marcal-Dekker, 2003.

19. Cornelius JR, Bukstein OG, Salloum IM, Clark DB: Alcohol and psychiatric

comorbidity. In, Galanter M (Ed), Recent Developments in Alcoholism: Research on

Alcoholism Treatment (v. 16) (pp. 361-374). Norwell, MA: Kluwer Academic, 2005.

20. Bukstein OG, Cornelius JR: Psychopharmacology of adolescents with substance use

disorders: using diagnostic specific treatments. In, Liddle HA, Rowe CL (Eds.), Adolescent

Substance Abuse: Research and Clinical Advances. (pp. 241-263). Cambridge, UK;

Cambridge University Press, 2005.

21. Bukstein OG, Tarter R.: Substance use disorders. In, Coffey CE, Brumback RA(Eds),

Pediatric Neuropsychiatry. (pp. 321-341). Philadelphia, PA: Lippincott Williams &

Williams, 2005.

22. Bukstein OG, Lutka-Fedor T: Principles of assessment for adolescents with substance use

disorders. In, Gilvarry E, McArdle P (Eds.), Alcohol, Drugs and Young People. (pp. 127-

135). Newcastle Upon Tyne, England: Mac Keith Press, 2007.

23. Bukstein OG, Lutka-Fedor T: Assessment instruments and outcome measurement. In

Gilvarry E, McArdle P (Eds.), Alcohol, Drugs and Young People. (pp. 136-149). Newcastle

Upon Tyne: England: Mac Keith Press, 2007.

24. Szobot, Claudia M and Bukstein, O. Substance Use Disorders in Adolescence. In: Advances

in Biological Psychiatry – Biological Child Psychiatry. Basel:Karger, 24: 166-180, 2008.

25. Bukstein, O: Adolescent Substance Abuse. In: Sadock BJ, Sadock VA, Ruiz (Eds.),

Comprehensive Textbook of Psychiatry, 9th Edition. (pp3818-3813). Philadelphia: Wolters

Kluwer/Lippincott Williams & Wilkins, 2009.

26. Bukstein OG, Deas D: Substance Abuse and Addictions. In: Dulcan MK (Ed.), Dulcan’s

Textbook of Child and Adolescent Psychiatry. ((pp. 241-260). Washington, DC: American

Psychiatric Press, INC, 2009.

27. Bukstein OG. Attention Deficit Hyperactivity Disorder and Substance Use Disorders. In

Stanford C and Tannock R (eds.), Behavioral Neuroscience of Attention Deficit

Hyperactivity Disorder and Its Treatment, Current Topics in Behavioral Neurosciences

(pp146-172). Berlin Heidelberg: Springer‐Verlag 2011.

28. Cornelius JR, Bukstein OG, Clark DB, Matta JK, Salloum IM: Fluoxetine trial for the

cannabis-related symptoms of comorbid adolescents. In, Walcott TA (Ed.), Drug and

Alcohol Abuse Research Focus. Hauppauge NY; Nova Science Publishers, in press

29. Other Non-refereed Publications:

Walter, HJ, Bukstein, OG: Clinical practice guidelines: Drs. Walter and Bukstein reply. J Am

Acad Child Adolesc Psychiatry, 46:940-942, 2007.

Bukstein, OG Taking Note of Over-the-Counter Remedies for Adolescents with Cannabis

Dependence. Am J. Psychiatry, 169:771-773, 2012.



19

III. Teaching Information

A. Didactic course work

1. Courses taught at University of Texas: (number of annual hours)

a. Disruptive Behaviors (including ADHD, Substance Use Disorders, QAggressive

behavior; 12 hours 10/10-6/13

b. Developmental neuroscience: 10 hours 10/10-7/13

c. Adult ADHD: 2 hours, 10/10-7/13

d. Miscellaneous child therapies: CBT, PMT: 5 hours 10/10-7/13

e. Motivational Interviewing (Adults and Adolescents): 12 hours 12/12-4/13

2. Courses taught at University of Pittsburgh

1. Annual In-service Presentations to Staff at Western Psychiatric Institute and Clinic on

Adolescent Substance abuse, Attention-Deficit Hyperactivity Disorder and other

Disruptive Behavior Disorders and Diagnosis of Childhood Disorders 1988-2010

2. Pediatric Psychopharmacology, lecture for Dr. Susan Campbell’s undergraduate child

psychopathology class 1993

3. Annual Lecture, Aggressive Behavior in children and Adolescents (PGY-III) 1993-2003

4. Faculty Facilitator, Faculty and Students Together (FAST) Program 1994-1996

5. Semi-annual lecture on Assessment of Children and Adolescents (PGY-I) 1994-2005

6. Clinical Neuroscience Clerkship, PBL: ADHD1995-2004

7. Children’s Hospital of Pittsburgh, Adolescent Clinic noon conference series, annual

lectures on ADHD and adolescent substance use disorders 1996-2010

8. Faculty Facilitator, Introduction to Being a Physician Course 1997-1998

9. Faculty Facilitator, Human Behavior Course - MS-II, Problem-Based Learning 1998-

2010

10. Organizer and presenter, Disruptive Behavior Disorders and Substance Use Disorders

Course (PGY-IV): ADHD, pharmacologic treatments, and adolescent substance use

disorders 1998-2010

11. NIMH Undergraduate Research Fellowship Program: (5 hours/year) 2001-2010

12. Annual and semi-annual training to trainees, staff and junior faculty in Motivational

Interviewing: 10 hours/year, 2002-2010

m. Psychiatric Epidemiology & Alcohol Research Seminar, lecture, Comorbidity of

Substance Use and Disorders in Adolescents (3/14/03)

n. Psychiatric Epidemiology & Alcohol Research Seminar, lecture, Depression and Alcohol

use Disorders in Female Adolescents (12/9/05)

o. WPIC Wide Journal Club, discussant (3/31/06; 6/1/06; 2/8/07; 1/10/08) 2005-2008

Organizer and presenter, Adult ADHD Course for Psychiatry Residents (PGY-III)

p. Advanced Psychopharmacology Class (PGY-III): ADHD Medications 2007-2010

Children’s Hospital of Pittsburgh, Pediatric resident noon conference series (1/16/08)

B. Non-didactic Teaching

1. Teaching and supervision of medical students at all levels: (average 3 hours/week) 1983-

2013

2. Teaching and supervision of psychiatry, family practice residents and nurse practitioner

students (average 1 per month): 1988-2010

3. Specific Supervision of Medical Students (University of Pittsburgh):

1) Nicole Christian, University of Pittsburgh SOM, Mentor, Scholarly Project, ADHD in a

Detention Center Population 7/2005-6/2008

2) Patrick Mc Garry, University of Pittsburgh SOM, Mentor, Scholarly Project, Prevalence and

motives for illicit use of prescription stimulants among undergraduate students 6/2006-5/2009


http://navigator.medschool.pitt.edu/34_viewModule.asp?moduleID=1992228802


20

3) Brain Slater, summer fellowship, Compliance in Adolescent Intensive Outpatient Therapy for

Substance Use Disorders 6/2007-10/2007

4) Caroline Nguyen, University of Pittsburgh SOM, Mentor, Scholarly Project 6/2008 -12/2010

5) Yulia Proosaselts. University of Pittsburgh SOM, Mentor, Scholarly Project 6/2010-8/2010

Other (University of Texas)

Angela Nash, UTHSC-H SON. Mentor, Doctoral dissertation 4/2011-present

4. SPONSORSHIP OF POSTDOCTORAL FELLOWS

a. Psychiatric Residents/ Fellows (Western Psychiatric Institute and Clinic):

1) Theresa Lutka-Fedor, Principles of Assessment for Adolescents with SUDs 7/2004-6/2005

2) Abigail Schlesinger, Tiffany Franchione, New Castle Youth Dev’ment Center 7/2004-6/2006

3) Mark Demidovich, Medication Refusal in ODD or CD Children with Comorbid ADHD:

Medication History and Clinical Correlates 7/2005-6/2009

4) Susan Morine, Treatment for Adolescent Substance Use Disorders 7/2006-7/2009

b. Faculty (Junior) and Other Post-Doctoral:

1) W. Burle Daviss, M.D. ADHD and Depressive Disorders in Children and

Adolescents 6/2000-6/2006

2) Tad Gorske, Ph.D. Effects of Cognitive Test Feedback on Patient Adherence 6/2004-

7/2008

3) Jeffrey Burke, Ph.D. Parental Help-seeking for Children’s Disruptive Behavior

9/2005-10/2010

4) Claudia Szobot, MD, postdoctoral fellow supported by her home institution, Center

for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal

University of Rio Grande do Sul, Brazil 6/2006-12/2009

5) Ben Goldstein, M.D. Family focused treatment for adolescents with bipolar disorder

and substance use disorders 6/2006-10/2009

6) Abigail Schlesinger, M.D., Services for ADHD in Primary Care 6/2006-7/2008

7) Srihari Bangelore, M.D., Frontal lobe Deficits in Children 6/2009-10/2012

C. Lectures: (include location, title of presentation, dates)

Evaluation of Adopted Children. Grand Rounds, Western Psychiatric Institute and Clinic

January 10, 1986

Depression and Substance Abuse. D'ART Conference, Pittsburgh, PA December 15,

1988

Dual-Diagnosis: Depression and Substance Abuse. Presentation and workshop, Office of

Education and Regional Programming (OERP), Washington, PA March 9, 1989

Genetics and Scientific Update in Diagnosis '89. Conference, Allegheny County

Medical Society, Pittsburgh, PA October 13, 1990

Administrative Issues in a Dual-Diagnosis Program, Grand Rounds, Department of

Psychiatry, West Virginia University January 26, 1990

Dual Diagnosis in Adolescents, Office of Education and Regional Programming (OERP):

Western Pennsylvania Regional Teleconference February 7, 1990

Adolescent Substance Abuse: Assessment and Treatment, Workshop, Annual

Conference for Services for Teens at Risk (STAR), Pittsburgh, PA March 16,

1990



21

Dual Diagnosis in Adolescents, Office of Education and Regional Programming, Butler,

PA November 8, 1991

Dual Diagnosis in Adolescents, Office of Education and Regional Programming,

Western Psychiatric Institute and Clinic, Greensburg, PA December 11, 1991

Dual Diagnosis in Adolescents, Workshop, Youth Development Center, New Castle, PA

February 26, 1992 November 1, 1994

The Adolescent MISA Consumer. Pennsylvania Child/Adolescent Intensive Case

Management Training, State College, PA December 2, 1994

Disruptive Behavior Disorders: DSM-IV Update Teleconference, Office of Educational

and Regional Programming (OERP) January 11, 1995

Bullying, Counselor Conference, Allegheny Intermediate Unit, Pittsburgh, PA January

13, 1995

Dual Diagnosis in Adolescents, Office of Education and Regional Programming (OERP):

Western Pennsylvania Regional Teleconference March 1, 1995

Emergency Services for Children and Adolescents, Workshop at Conference:

"Emergency Psychiatry: Current Practice, Future Directions," Pittsburgh, PA

September 15, 1995

Mood and Conduct Disorders in Delinquent Youth, Youth Development Center, New

Castle, PA May 13, 1996

Psychopharmacology for Detained Youth, Juvenile Detention Center Association of

Pennsylvania, State College, PA May 23, 1996

Attention-Deficit Hyperactivity Disorder. Annual Meeting of the Pennsylvania

Association for Physicians Assistants, Pittsburgh, PA October 12, 1996

Mental Health Problems of Delinquents Office of Education and Regional Programming

(WPIC), St. Mary's, PA May 8, 1998

Mental health and Juvenile Justice May 8, 1998

Mental Health and Delinquency, Trouble Youth Conference, WPIC Office of

Education and Regional Programming (OERP), Moon, PA April 29, 1999

Troubled Youth: How Can the Profesisonal Help. Office of Education and Regional

Programing (OERP). Pittsburgh, PA April 29, 1999

Adolescent Treatment Update, Dual Diagnosis: 10 Years of Progress Conference, Center

for Psychiatry and Chemical Dependency Services, Pittsburgh, PA May 21, 1999

Attention Deficit Hyperactivity Disorder, Excellence in Mental Health in Schools

Conference, Carlisle, PA May 21, 2000

Psychopharmacology for Detained Youth, Juvenile Detention Center Association of

Pennsylvania Annual Meeting, State College, PA October 12, 2000

Current Issues in Attention Deficit Hyperactivity Disorder, Grand Rounds, Department

of Pediatrics, Mercy Hospital, Pittsburgh, PA November 14, 2000

Attention Deficit Hyperactivity and Substance Use Disorders, Grand Rounds,

Department of Psychiatry, Allegheny General Hospital, Pittsburgh, PA January

18, 2001

MISA in Adolescents, Office of Education and Regional Programing (OERP)

videoconference January 24, 2001

Psychopharmacology of Substance Use Disorders in Adolescents, Western Psychiatric

Institute and Clinic, Pittsburgh, PA January 26, 2001

The Assessment and Treatment of ADHD, Office of Education and Regional Programing

(OERP), New Castle, PA May 11, 2001

New Directions for Adolescent Substance Abuse. Office of Education and Regional

Programing (OERP). Hamarville, PA March 23, 2004

ADHD in Adults, Grand Rounds, Department of Psychiatry, Allegheny General

Hospital, Pittsburgh, PA April 22, 2004



22

ADHD in Adults, Update in Internal Medicine, UPMC, Pittsburgh, PA November 19,

2004

ADHD in Adults, WPIC Staff Development December 2, 2004

Student Services Update: Substance Abuse and Psychaitric Issues – Ask the

Experts. Office of Education and Regional Programing (OERP), Pittsburgh, PA

January 31, 2006

Allegheny County DUI workshop; Risk Factors and Assessment of Adolescents with

alcohol Problems April 11, 2006

ADHD in Adults, Office of Education and Regional Programing (OERP), Mayville Sate

Hsopital, Pittsburgh, PA May 18, 2006

High School SAP Update, Diocese of Pittsburgh, Pittsburgh, PA June 27, 2006

Self-Injurious Behaviors and Adolescents, The Allegheny-Kiski Health

Foundation, New Kensington, PA November 15, 2006

ADHD in a Juvenile Detention Center Allegheny County Juvenile Court,

Monroeville, PA November 29, 2006

Adult ADHD, Office of Education and Regional Programing (OERP) Videoconference

January 17, 2007

Best practices for Integrating Treatment and Support for Adolescents with Co-Occurring

Disorders. Office of Education and Regional Programing (OERP), Monaca, PA

November 30, 2007

Treating ADHD and Substance Abuse with Adolescents. West Virginia Addiction

Training Institute, Morgantown, WV June 9, 2009

Comorbidity with Substance Abusing Adolescents West Virginia Addiction Training

Institute, Morgantown, WV June 9, 2009

IV. Medical & Service Information

A. Patient care responsibilities – University of Texas

1. UT Psychiatry Outpatient Services 11/10-6/13

2. South Region Collaborative outpatient serves 10/11-6/13

3. Children’s Assessment Center Outpatient services 4/11-6/13

4. Harris County Psychiatric Center Residential Treatment Program 7/11-6/12

B. Service to the Community

Task Force/Advisory Committee for Drug and Alcohol Abuse Training, Commonwealth

of Pennsylvania 1990 - 1991

Pro Bono Mental Health Project, Pittsburgh Women’s Shelter – Volunteer 1991-93

Member, Psychiatry Faculty-Medical Student Mentor Program 1996-Present

President, Pittsburgh Regional Organization of Child and Adolescent Psychiatry 2000-

2003

Substance Abuse Panel chair, the Health, Mental Health and Safety Guidelines for

Schools Project, sponsored by the American Academy of Pediatrics and the

National Association of School Nurses 2000-2004

Allegheny County Children’s Cabinet, Subcommittee on Mental Health and Juvenile

Justice 2001-2003

Member, Juvenile Detention Centers of Pennsylvania (JDCAP) Mental Health

Advisory Committee 2001-Present

Member, Allegheny County Public Psychiatry Advisory Group 2002-Present

Judge: “When Not to Keep a Secret” National High School Essay Contest,

Pennsylvania Psychiatric Society 2002



23

Work Group on Services for Youth with Substance Abuse or Co-occurring Disorders,

Bureau of Children's Services – OMHSAS, Commonwealth of Pennsylvania

2004-2006

Consultation:

Child and Adolescent Psychiatric Evaluations and Consultation to Turtle Creek Valley

Mental Health/Mental Retardation Center, PA 1986-1988

Consultation to Administrative and Clinical Staff, Fayette County

Mental Health/Mental Retardation Program, Uniontown, PA 1986-1987

Emergency Outreach Program: screening students suicide(s) at local schools, Services

for Teens at Risk (STAR), Western Psychiatric Institute and Clinic1987-1992

Psychiatric Consultant, University of Pittsburgh Student Health Service and Student

Counseling Center 1988-1993

Psychiatric Consultant, Maximizing Adolescent Potentials (MAPS), School Of

Education, University of Pittsburgh 1988-Present

Psychiatric Consultant, Shuman Juvenile Detention Center of Allegheny County and

Allegheny County Juvenile Court 1993-Present

Consultant, Community Care Behavioral Health (CCBH), Pittsburgh, PA 1996-Present

U.S. Department of Health and Human Services, Center for Substance Abuse Prevention

(CSAP); training and consultation to various state and local agencies. 1996-

Present

External Consultant University of Miami, Howard Liddle (PI). Technology Transfer of

Multidimensional Family Therapy. Center for Treatment Research on Adolescent Drug

Abuse, University of Miami, Florida 2000-2003

Consultation to pharmaceutical companies (Alza Corp., McNeil Pediatrics, Shire

Pharmaceuticals, Cephalon) 2000-2007

Internal Consultant, University of Pittsburgh, Tammy Chung, (PI)

Diagnostic Criteria for Adolescent Alcohol Use Disorders, 2001-2006, NIAAA,

K01- Award. 2001-2006

National Institute on Drug Abuse (NIDA), Clinical Trials Network 2003-2005

University of Pittsburgh, Ralph Tarter (PI): Member Data and Safety Monitoring

Board (DSMB), The Center for Education and Drug Abuse Research (CEDAR)

(Funding: NIDA) 2004-2010

Internal Consultant, University of Pittsburgh, Tammy Chung, (PI)

Course of Alcohol and Drug Problems in Treated Teens, (Funding: NIAAA)

2004-2009

Internal Consultant, University of Pittsburgh, Tammy Chung, (PI) Mechanisms of Change

in Alcohol Treatment for Dually Diagnosed Youth 2007-Present

University of Pennsylvania, University of Pittsburgh: Chair, Data and Safety

Monitoring Board (DSMB), PA Adolescent Smoking Study (PASS Study) (funding: PA

State Tobacco Fund) 2007-Present

External Consultant, James Madison University, Steve Evans (PI): Treatment

Development for High School Students with ADHD (funding: NIMH) 2007-Present

University of Pittsburgh, Michael Marshall (PI): Understanding the Health and

Wellness of Pittsburgh Youth (funding: Pittsburgh Foundation) 2007-Present

Columbia University, Francis Levin (PI): Member of DSMB, Extended-Release

Amphetamine Salts for Adult ADHD and Cocaine Dependence (Funding: NIDA)

2008-Present

Faculty, Lone Star LEND (autism training center) at UTHSC-H (funding: NICHD) 2011-

Present



24

C. Service to the University

1. UT Medical School At Houston-Department of Psychiatry & Behavioral Sciences

Chief/Director, Division of child and Adolescent Psychiatry 10/2010-7/2013 Member, Child/Adolescent Psychiatry Fellowship Committee 10/2010- 7/2013

Member, Department of Psychiatry Clinical Operations Committee 10/2010- 7/2013

Member, Department of Psychiatry Executive Committee 10/2010- 7/2013

Chair, Department of Psychiatry Grand Rounds Committee 10/2010- 6/2013

2. Service to the University of Pittsburgh

Vice President, Western Psychiatric Institute and Clinic House Staff Association 1985-

1986

Member of training faculty for Alcohol Research Training Program, Department of

Psychiatry, University of Pittsburgh. Dr. Marie Cornelius, Director. 1990-2010

Member of training faculty for Clinical Research Training in Child Psychiatry, Department

of Psychiatry, University of Pittsburgh. David A. Brent, MD, Director. 1990-2010

Member, Institutional Review Board, University of Pittsburgh 2003-2010

Vice-chair, Institutional Review Board, University of Pittsburgh 2007-2010


response of debtors to the reports of eric m....

Documents